Safety and Efficacy of Tremelimumab+Durvalumab(MEDI4736)+TACE in Unresectable Hepatocellular Carcinoma
Conditions
- Hepatocellular Carcinoma (HCC)
- Unresectable Hepatocellular Carcinoma
Interventions
- DRUG: Tremelimumab Plus Durvalumab (MEDI4736)
- PROCEDURE: Transarterial chemoembolization (TACE)
Sponsor
Yoon Jun Kim
Collaborators